Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BTK inhibitors
Pharma
Zenas gains MS hopeful in $2B deal with China's InnoCare
Eying an MS drug with potential peak sales projections of $12B, Zenas has struck a licensing deal with InnoCare that could be worth more than $2B.
Kevin Dunleavy
Oct 8, 2025 11:50am
AbbVie, BeOne end BTK inhibitor patent fight
Oct 2, 2025 10:29am
Novartis' BTK inhibitor wins FDA approval in chronic hives
Sep 30, 2025 6:40pm
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
Sanofi's Wayrilz snags FDA endorsement in ITP
Aug 29, 2025 5:59pm
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
